Forecast

The analysts' average price target is +18,03€ (+286,91%). The median is +18,03€ (+286,91%).

Buy	13
Hold	5
Sell	1

News Go to news feed

EU grants Vanda orphan drug status for imsidolimab in generalized pustular psoriasis

The European Commission has granted orphan drug status to Vanda’s investigational treatment imsidolimab for generalized pustular psoriasis (GPP), based on a recommendation from the EMA’s committee for rare diseases. It is the first agent to receive this designation for GPP in the EU; the FDA and Japan had previously awarded orphan status. The FDA is currently reviewing the biologics license application for imsidolimab, with a target decision date of December 12, 2026. Vanda holds an exclusive worldwide license; regulatory and patent exclusivity are expected into the late 2030s, along with benefits such as scientific advice, reduced fees, and market exclusivity. » More on de.investing.com
Vanda misses Q2 forecasts and reports significantly higher loss

Vanda reported an adjusted loss of $1.04 per share in the second quarter versus the $0.60 expected and revenue of $50.5 million (expectation $61.8 million). Strong prescription growth for Fanapt and moderate growth for PONVORY could not offset a sharp decline in HETLIOZ due to generic competition. Operating expenses rose markedly, the net loss widened to $62.5 million, and cash on hand stood at $170 million as of June 30. Vanda reconfirmed its full-year revenue guidance of $240–290 million, expects costs to decline from late 2026/2027, and pointed to several upcoming Phase III milestones and a PDUFA date in December 2026. » More on de.investing.com
Vanda Pharmaceuticals: EMA committee recommends orphan-drug status for imsidolimab in GPP

The EMA's Committee for Orphan Medicinal Products has issued a positive opinion to grant orphan-drug status to imsidolimab for the treatment of generalized pustular psoriasis (GPP), the first designation for GPP in the EU. The designation provides benefits such as scientific advice, reduced regulatory fees and potential market exclusivity after approval. Imsidolimab is a humanized monoclonal antibody, and its BLA application is under review by the FDA with a decision due by December 12, 2026. Despite the regulatory progress, Vanda's stock is down about 33.67% year-to-date; analysts have price targets up to $21 and note a solid balance sheet with more cash than debt. » More on de.investing.com

Financials

In the last quarter, Vanda Pharmaceuticals had revenue of 44.27m€ and net profit of −54.77m€

(EUR)	Jun 2026	YoY
Revenue	+44.27m	0,77%
Gross profit	+41.15m	0,84%
Net profit	−54.77m	137,29%
EBITDA	−55.42m	98,72%

Fundamentals

Metric	Value
Market capitalization	+276.28m€
Number of shares	60.14m
52-week high/low	+8,54€ - +3,67€
Dividends	No
Beta	0,64
P/E ratio	−1,16
PEG ratio	+0,01
P/B ratio	+1,46
P/S ratio	+1,49

Company profile

Vanda Pharmaceuticals Inc. ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung und Vermarktung von Therapien konzentriert, die einen hohen ungedeckten medizinischen Bedarf decken. Zu den vermarkteten Produkten des Unternehmens gehören HETLIOZ zur Behandlung von Schlaf-Wach-Störungen, die nicht über 24 Stunden andauern, und Fanapt Tabletten zur Behandlung von Schizophrenie. Zu den in der Entwicklung befindlichen Produkten gehören HETLIOZ (Tasimelteon) zur Behandlung von Jetlag-Störungen, Smith-Magenis-Syndrom, pädiatrischem Non-24, Autismus-Spektrum und verzögerter Schlafphasenstörung; Fanapt (Iloperidon) zur Behandlung von bipolaren Störungen und ein Programm für eine lang wirkende injizierbare Formulierung zur Behandlung von Schizophrenie; und Tradipitant (VLY-686), ein niedermolekularer Neurokinin-1-Rezeptor (NK-1R)-Antagonist, zur Behandlung von atopischer Dermatitis, Gastroparese und Reisekrankheit. Zu den in der Entwicklung befindlichen Produkten des Unternehmens gehören auch VTR-297, ein niedermolekularer Histon-Deacetylase-Inhibitor zur Behandlung von hämatologischen Malignomen und mit potenzieller Verwendung zur Behandlung verschiedener onkologischer Indikationen; VQW-765, ein niedermolekularer partieller Agonist des nikotinischen Acetylcholinrezeptors zur Behandlung psychiatrischer Störungen; ein Portfolio von Aktivatoren und Inhibitoren des Mukoviszidose-Transmembranleitfähigkeitsregulators zur Behandlung von trockenen Augen und Augenentzündungen sowie BPO-27 zur Behandlung von sekretorischen Durchfallerkrankungen, einschließlich Cholera, und VHX-896, der aktive Metabolit von Iloperidon. Das Unternehmen vertreibt seine Produkte in den Vereinigten Staaten, Europa und Israel. Vanda Pharmaceuticals Inc. wurde im Jahr 2002 gegründet und hat seinen Hauptsitz in Washington, District of Columbia.

Name	Vanda Pharmaceuticals
CEO	Mihael H. Polymeropoulos
Headquarters	Washington, dc USA
Website	vandapharma.com
Sector	Materials
Industry	Chemicals
IPO	04/12/2006
Employees	533